Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease

Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Rev... Biopharmaceuticals, Mergers & Acquisitions Bristol-Myers Squibb, Celgene

Source: HSMN NewsFeed - January 4, 2019 Category: Pharmaceuticals Source Type: news